FIELD: biotechnology.
SUBSTANCE: group of inventions refers to a composition for combined procaspase therapy containing a compound of formula 
and a PAC-1: 
compound, as well as a method for suppressing the growth and/or proliferation of glioblastoma cells, oligodendrogliomas or osteosarcomas; to the method for inducing apoptosis of brain cancer cells or bone cancer cells; to the method for treating brain cancer or bone cancer; and to the use of a composition for preparing a medicament for the treatment of brain cancer or bone cancer.
EFFECT: synergistic action of the composition components.
22 cl, 4 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY | 2013 |
|
RU2659936C2 |
| COMBINED THERAPY PAC-1 | 2016 |
|
RU2720509C2 |
| ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS | 2013 |
|
RU2652989C2 |
| METHOD FOR TREATMENT OF PATIENTS WITH LARGE INTESTINE CANCER OR LUNG CANCER | 2014 |
|
RU2713555C2 |
| COMPOSITIONS AND METHODS FOR INHIBITING T-CELL DEPUTY | 2018 |
|
RU2804282C2 |
| COMPLEX THERAPY FOR CANCER TREATMENT | 2018 |
|
RU2810487C2 |
| COMPOUND FOR TREATING CANCER | 2014 |
|
RU2708247C2 |
| BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC METHODS OF IMPLEMENTATION | 2013 |
|
RU2649975C2 |
| METHOD AND COMPOSITION FOR DIAGNOSING AND TREATING CANCER | 1996 |
|
RU2174409C2 |
| METHOD OF MODULATION OF EICOSANOID METABOLISM | 2006 |
|
RU2438684C2 |
